VERVE THERAPEUTICS INC (VERV) Stock News
NASDAQ:VERV - Nasdaq - US92539P1012 - Common Stock - Currency: USD
VERV Latest News, Press Relases and Analysis
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Verve Therapeutics (VERV) delivered earnings and revenue surprises of 50.70% and 362.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: PSTV
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates
Organogenesis (ORGO) delivered earnings and revenue surprises of -425% and 4.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ORGO
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.
Mentions: CRSP
Why Verve Therapeutics Is Skyrocketing Today
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street
Take Verve Therapeutics (NASDAQ: VERV), a small-cap, clinical-stage biotech. If Verve Therapeutics has any chance of soaring by more than 300% in the next year, the company will have to impress the market with its leading candidate, VERVE-102. Notably, Verve Therapeutics recently announced positive results from a Phase 1b clinical trial for VERVE-102 as a potential treatment for heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease.
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street
Carnival Is Down 27% in 2025. Is This a Once-in-a-Lifetime Buying Opportunity Before the Stock Goes Parabolic?
Carnival (NYSE: CCL) (NYSE: CUK) hasn't been immune to investors' worries about President Trump's latest taxation plans. First, following comments by Commerce Secretary Howard Lutnick, investors were concerned the Trump administration may increase taxation on cruise companies. All this has pushed Carnival's share price lower, leaving the stock down 27% so far this year.
Is Sirius XM Stock a Buy, Sell, or Hold in 2025?
Tuning in to Sirius XM (NASDAQ: SIRI) has been a static-filled experience for investors, with shares down 50% from their 52-week high at the time of writing. For income-focused investors, the stock's 5.2% dividend yield deserves some attention. Satellite radio is no longer the groundbreaking novelty it was when Sirius XM beamed its first commercial broadcast in 2002.
Why MP Materials Stock Was a Massive Winner This Week
Rare earth miner and processor MP Materials (NYSE: MP) had quite the week to remember, both operationally and on the stock market. On the back of some quite favorable news, the company's shares raced more than 16% higher over the course of the week, according to data compiled by S&P Global Market Intelligence. MP Materials owns and operates the only rare earth mine in the U.S. Rare earths, for those unfamiliar, are metals that are used in the manufacture of specialty magnets used in popular high-tech products such as smartphones.
Why Verve Therapeutics Zoomed 40% Higher This Week
Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (NASDAQ: VERV) big stock price leap this week. Verve is a clinical-stage biotech, so its success depends on how it's progressing with its pipeline. The indications were quite encouraging this week when the company published initial data from a phase 1b clinical trial of VERVE-102, a drug targeting heterozygous familial hypercholesterolemia (HeFH) -- a genetic disorder that causes high cholesterol levels -- and premature coronary artery disease.
Mentions: JPM
Sonoco Products Company (SON): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025
We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Sonoco Products Company (NYSE:SON) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide amid growing […]
Match Group, Inc. (MTCH): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025
We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Match Group, Inc. (NASDAQ:MTCH) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide amid growing […]
Is Integra Resources Corp. (ITRG) the Best Rising Penny Stock to Buy According to Analysts?
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Integra Resources Corp. (NYSEAMERICAN:ITRG) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]
Is Satixfy Communications Ltd. (SATX) the Best Rising Penny Stock to Buy According to Analysts?
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Satixfy Communications Ltd. (NYSEAMERICAN:SATX) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]
Is Bristol-Myers Squibb Company (BMY) The Dirt Cheap Stock To Invest In Now?
We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dirt cheap stocks to invest in now. Investor’s Guide to Navigating the Volatilitc The stock market has been experiencing volatility and has […]
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.
Why Verve Therapeutics Is Skyrocketing Today
Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy.
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill
Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the
Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke
European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too. Novartis’ latest move is a reactiv
Verve Shares Soar After New Gene-Editing Trial Shows No Safety Concerns
Verve Therapeutics Inc. shares jumped after the company reported no safety issues in a new study of its gene-editing treatment for people with high cholesterol.
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69%...
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol (LDL-C). VERVE-102 is the company’s novel, in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 is currently being tested in the Phase 1b Heart-2 clinical trial, which is designed to evaluate the safety and tolerability of VERVE-102 administration in adult patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD) who require additional lowering of LDL-C.
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Verve Therapeutics, Inc. (NASDAQ:VERV) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […]